Amvuttra (vutrisiran) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient has a transthyretin pathogenic variant confirmed by genetic testing
• Patient has symptomatic polyneuropathy
• Patient does not have a history of liver transplantation
• Medication is prescribed by or in consultation with a neurologist, geneticist, or a physician who specializes in the treatment of amyloidosis

Approval duration

1 year